HN2003000090A - Compuestos que modulan la actividad de ppar - Google Patents
Compuestos que modulan la actividad de pparInfo
- Publication number
- HN2003000090A HN2003000090A HN2003000090A HN2003000090A HN2003000090A HN 2003000090 A HN2003000090 A HN 2003000090A HN 2003000090 A HN2003000090 A HN 2003000090A HN 2003000090 A HN2003000090 A HN 2003000090A HN 2003000090 A HN2003000090 A HN 2003000090A
- Authority
- HN
- Honduras
- Prior art keywords
- ppar
- modulate
- activity
- compounds
- formulations
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title abstract 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000003054 hormonal effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36240202P | 2002-03-07 | 2002-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HN2003000090A true HN2003000090A (es) | 2004-05-05 |
Family
ID=27789157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HN2003000090A HN2003000090A (es) | 2002-03-07 | 2003-03-06 | Compuestos que modulan la actividad de ppar |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20030207924A1 (https=) |
| EP (1) | EP1482935B1 (https=) |
| JP (1) | JP2005528348A (https=) |
| KR (1) | KR20040091693A (https=) |
| AP (1) | AP2004003124A0 (https=) |
| AR (1) | AR038881A1 (https=) |
| AT (1) | ATE405260T1 (https=) |
| AU (1) | AU2003206059A1 (https=) |
| BR (1) | BR0308277A (https=) |
| CA (1) | CA2478520A1 (https=) |
| CO (1) | CO5601012A2 (https=) |
| DE (1) | DE60323060D1 (https=) |
| EA (1) | EA200400943A1 (https=) |
| EC (1) | ECSP045285A (https=) |
| ES (1) | ES2310650T3 (https=) |
| HN (1) | HN2003000090A (https=) |
| IS (1) | IS7377A (https=) |
| MA (1) | MA27181A1 (https=) |
| MX (1) | MXPA04007564A (https=) |
| NO (1) | NO20044242L (https=) |
| OA (1) | OA12780A (https=) |
| PA (1) | PA8567801A1 (https=) |
| PE (1) | PE20030989A1 (https=) |
| PL (1) | PL372969A1 (https=) |
| TN (1) | TNSN04168A1 (https=) |
| TW (1) | TW200305403A (https=) |
| UY (1) | UY27695A1 (https=) |
| WO (1) | WO2003074050A1 (https=) |
| ZA (1) | ZA200406068B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
| US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| US7244763B2 (en) * | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| MXPA05012459A (es) * | 2003-05-19 | 2006-02-22 | Irm Llc | Compuestos y composiciones inmunosupresoras. |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| CA2558585C (en) | 2004-02-27 | 2010-10-12 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| ES2352085T3 (es) | 2004-05-05 | 2011-02-15 | High Point Pharmaceuticals, Llc | Nuevos compuestos, su preparación y uso. |
| WO2005105736A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| AU2012200214B2 (en) * | 2004-05-14 | 2013-10-24 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| WO2005115384A2 (en) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation |
| CN1997633A (zh) * | 2004-05-25 | 2007-07-11 | 麦它波莱克斯股份有限公司 | 作为ppar调节剂的取代的三唑及其制备方法 |
| US20090054493A1 (en) * | 2005-02-25 | 2009-02-26 | Heonjoong Kang Kang | Thiazole derivatives as ppar delta ligands and their manufacturing process |
| CN101193876B (zh) * | 2005-05-07 | 2011-05-11 | 财团法人首尔大学校产学协力财团 | 制备PPARδ的配体的方法和用于制备该配体的中间化合物 |
| US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| ATE529404T1 (de) | 2005-06-30 | 2011-11-15 | High Point Pharmaceuticals Llc | Phenoxyessigsäuren als ppar-delta-aktivatoren |
| EP1916234B1 (en) * | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| EP1924546A1 (en) | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| BRPI0620468A2 (pt) | 2005-12-22 | 2011-11-08 | Transtech Pharma, Inc. | ácidos fenóxi acéticos como ativadores de ppar delta |
| JP2009132620A (ja) * | 2006-03-07 | 2009-06-18 | Astellas Pharma Inc | フェニルチアゾール誘導体 |
| WO2007101864A2 (en) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Compounds that modulate ppar activity, their preparation and use |
| EP2064193A1 (en) | 2006-09-07 | 2009-06-03 | Amgen, Inc | Heterocyclic gpr40 modulators |
| CA2662242C (en) | 2006-09-07 | 2012-06-12 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
| AU2008241490B2 (en) | 2007-04-16 | 2011-07-21 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators |
| US8030354B2 (en) | 2007-10-10 | 2011-10-04 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
| AU2008338963A1 (en) * | 2007-12-13 | 2009-06-25 | Sri International | PPAR-delta ligands and methods of their use |
| WO2009086277A1 (en) | 2007-12-20 | 2009-07-09 | Envivo Pharmaceuticals, Inc. | Tetrasubstituted benzenes |
| WO2009111056A1 (en) | 2008-03-06 | 2009-09-11 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
| AU2009303475B2 (en) | 2008-10-15 | 2012-09-13 | Amgen Inc. | Spirocyclic GPR40 modulators |
| EP2540711A4 (en) * | 2010-02-25 | 2014-01-22 | Snu R&Db Foundation | Selenium-Zolderivate with ligand for the activation of the peroxisome-proliferator-activated receptor (PPAR), preparation method therefor and use of the chemical compounds |
| WO2015035171A1 (en) | 2013-09-09 | 2015-03-12 | High Point Pharmaceuticals, Llc | Use of a ppar-delta agonist for treating muscle atrophy |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
| CN1233241A (zh) * | 1996-08-19 | 1999-10-27 | 日本烟草产业株式会社 | 丙酸衍生物及其用途 |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| GB0031107D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| AU2002233271A1 (en) * | 2000-12-20 | 2002-07-01 | Glaxo Group Limited | Substitued oxazoles and thiazoles as hppar alpha agonists |
| GB0111523D0 (en) * | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
| HRP20031002A2 (en) * | 2001-06-07 | 2004-06-30 | Lilly Co Eli | Modulators of peroxisome proliferator activated receptors (ppar) |
-
2002
- 2002-12-20 US US10/324,148 patent/US20030207924A1/en not_active Abandoned
-
2003
- 2003-02-24 AU AU2003206059A patent/AU2003206059A1/en not_active Abandoned
- 2003-02-24 PL PL03372969A patent/PL372969A1/xx not_active Application Discontinuation
- 2003-02-24 DE DE60323060T patent/DE60323060D1/de not_active Expired - Fee Related
- 2003-02-24 AP APAP/P/2004/003124A patent/AP2004003124A0/en unknown
- 2003-02-24 OA OA1200400232A patent/OA12780A/en unknown
- 2003-02-24 BR BR0308277-6A patent/BR0308277A/pt not_active IP Right Cessation
- 2003-02-24 WO PCT/IB2003/000708 patent/WO2003074050A1/en not_active Ceased
- 2003-02-24 JP JP2003572567A patent/JP2005528348A/ja not_active Abandoned
- 2003-02-24 MX MXPA04007564A patent/MXPA04007564A/es active IP Right Grant
- 2003-02-24 ES ES03702943T patent/ES2310650T3/es not_active Expired - Lifetime
- 2003-02-24 AT AT03702943T patent/ATE405260T1/de not_active IP Right Cessation
- 2003-02-24 EA EA200400943A patent/EA200400943A1/ru unknown
- 2003-02-24 EP EP03702943A patent/EP1482935B1/en not_active Expired - Lifetime
- 2003-02-24 CA CA002478520A patent/CA2478520A1/en not_active Abandoned
- 2003-02-24 KR KR10-2004-7013951A patent/KR20040091693A/ko not_active Ceased
- 2003-02-27 PA PA20038567801A patent/PA8567801A1/es unknown
- 2003-03-04 PE PE2003000210A patent/PE20030989A1/es not_active Application Discontinuation
- 2003-03-05 AR ARP030100737A patent/AR038881A1/es unknown
- 2003-03-06 TW TW092104790A patent/TW200305403A/zh unknown
- 2003-03-06 UY UY27695A patent/UY27695A1/es not_active Application Discontinuation
- 2003-03-06 HN HN2003000090A patent/HN2003000090A/es unknown
-
2004
- 2004-07-29 IS IS7377A patent/IS7377A/is unknown
- 2004-07-29 ZA ZA200406068A patent/ZA200406068B/en unknown
- 2004-08-24 CO CO04082302A patent/CO5601012A2/es not_active Application Discontinuation
- 2004-08-30 MA MA27839A patent/MA27181A1/fr unknown
- 2004-09-03 TN TNP2004000168A patent/TNSN04168A1/fr unknown
- 2004-09-07 EC EC2004005285A patent/ECSP045285A/es unknown
- 2004-10-06 NO NO20044242A patent/NO20044242L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1482935B1 (en) | 2008-08-20 |
| UY27695A1 (es) | 2003-10-31 |
| AP2004003124A0 (en) | 2004-09-30 |
| NO20044242L (no) | 2004-10-06 |
| EP1482935A1 (en) | 2004-12-08 |
| ECSP045285A (es) | 2004-10-26 |
| MA27181A1 (fr) | 2005-01-03 |
| ATE405260T1 (de) | 2008-09-15 |
| TW200305403A (en) | 2003-11-01 |
| DE60323060D1 (de) | 2008-10-02 |
| US20030207924A1 (en) | 2003-11-06 |
| AU2003206059A1 (en) | 2003-09-16 |
| CA2478520A1 (en) | 2003-09-12 |
| WO2003074050A1 (en) | 2003-09-12 |
| PA8567801A1 (es) | 2003-11-12 |
| IS7377A (is) | 2004-07-29 |
| PL372969A1 (en) | 2005-08-08 |
| CO5601012A2 (es) | 2006-01-31 |
| JP2005528348A (ja) | 2005-09-22 |
| OA12780A (en) | 2006-07-07 |
| ES2310650T3 (es) | 2009-01-16 |
| PE20030989A1 (es) | 2003-11-29 |
| BR0308277A (pt) | 2004-12-28 |
| TNSN04168A1 (fr) | 2007-03-12 |
| MXPA04007564A (es) | 2004-11-10 |
| KR20040091693A (ko) | 2004-10-28 |
| EA200400943A1 (ru) | 2005-02-24 |
| AR038881A1 (es) | 2005-02-02 |
| ZA200406068B (en) | 2005-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HN2003000090A (es) | Compuestos que modulan la actividad de ppar | |
| HN2003000113A (es) | Compuestos que modulan la actividad ppar y procedimientos para su preparacion | |
| NI200300039A (es) | Compuestos que modulan la actividad de ppar. | |
| GT200500137A (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis. | |
| PA8568701A1 (es) | Compuestos que modulan la actividad de ppar | |
| CL2017003288A1 (es) | Métodos para tratar o prevenir enfermedades relacionadas con el colesterol (divisional solicitud 201303214) | |
| BR112019001923A2 (pt) | moduladores de nmda de espiro-lactama e métodos de sua utilização | |
| BRPI0411900B8 (pt) | compostos e composições farmacêuticas compreendendo os mesmos | |
| SV2003001493A (es) | Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion | |
| CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
| CR10900A (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso los mismos | |
| AR052238A1 (es) | Formulacion de tabletas estables | |
| GT200100199A (es) | Nuevos retinoides para el tratamiento de efisema. | |
| CR8926A (es) | Acidos de tiazolo-naftilo | |
| AR021643A1 (es) | Combinacion de cerivastatina y fibratos. | |
| BR112019001921A2 (pt) | moduladores do receptor nmda de espiro-lactama e seus usos | |
| GT200000077A (es) | Sal mutua de amlodipino y atorvastatina | |
| MX2022006176A (es) | Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2. | |
| CR10524A (es) | Compuesto triciclico y uso farmaceutico del mismo | |
| CL2012001671A1 (es) | Compuestos derivados de (metilsulfonil)-etil-bencenoisoindolina; composicion farmaceutica que los comprende, uso en el tratamiento del cancer, dolor, trastornos del snc, enfermedades dermatologicas, entre otras. | |
| HN2000000045A (es) | Nuevas combinaciones farmaceuticas para inhibidores de la nos. | |
| UY26265A1 (es) | Compuestos calciolíticos | |
| BR112022012485A2 (pt) | Agente profilático e/ou terapêutico para prostatite crônica/síndrome de dor pélvica crônica | |
| HRP20050579B1 (hr) | Nove sinergistiäśne kombinacije koje sadrže roflumilast i formoterol | |
| CR9426A (es) | Utilizacion de agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos bipolares |